Market Overview –
At a compound annual growth rate (CAGR) of 17.05% between 2022 and 2030, the global Epigenetics Market is expected to grow from a value of USD 2.86 billion in 2021 to USD 11.83 billion by 2030. The field of epigenetics investigates how cellular processes can regulate genes without directly affecting DNA sequence. The Greek prefix “epi” means “above,” hence the term “epigenetic” describes factors outside of DNA. In order to activate or silence genes, epigenetic modifications must be made to the DNA. The order of the DNA’s constituent parts is unaffected by these mutations. All of the DNA modifications that influence gene expression occur in the epigenome of a cell (expression). Epigenetic modifications switch on and off genes, hence influencing protein synthesis in cells.
This regulation guarantees that cells only produce the proteins that are actually needed. However, muscle cells do not produce bone-growth proteins. Changes in epigenetics exhibit a wide range of variability between individuals, organs, and even individual cells. Food and environmental pollution are two examples of factors that might alter the epigenome. Changes in epigenetics can be replicated from cell to cell and even inherited from one generation to the next.
As sequencing prices drop, next-generation sequencing is adopted on a worldwide scale, and product quality rises, the epigenetics market is expected to flourish. There is a scarcity of epigenetics researchers and high costs associated with purchasing the equipment needed to conduct the necessary studies. These problems are preventing the market from growing. Epigenetic mechanisms like DNA methylation, histone modification, and non-coding RNA have a significant impact on epigenetic processes, and are thus being linked to a wide range of chronic diseases and disorders.
Market Dynamics –
There has been a global uptick in cancer incidence. As reported by the World Health Organization, there were over 2.1 million new cases of cancer worldwide in 2020. It is estimated that over 70% of all cancer deaths have occurred in low and middle income countries. One in four American deaths are caused by cancer. Disrupted DNA methylation has been associated to carcinogenesis and metastasis. Cancer’s dysregulation can now be treated in unique ways thanks to epigenetics research. Epigenetics is being used in a growing number of cancer studies, which are receiving substantial financing.
Extensive study of epigenetics has led to the development of drugs that are particularly effective against a specific type of cancer. Thereby, the global cost of healthcare can be reduced, allowing less fortunate countries to access treatment at reduced rates. As opposed to conventional cancer treatments, epigenetics permits targeted therapeutic activities that specifically target damaged and malignant cells within the host. Therefore, it is expected that a rise in the global cancer caseload would be a key factor propelling the epigenetics industry forward.
Impacts of the COVID-19 –
Across the previous several months, the global economy has been hit badly in a wide range of sectors. Because of precautionary lockdowns and other limitations imposed by governments around the world, both companies’ manufacturing and supply-chain operations were severely disrupted. The same holds true for the worldwide market for Epigenetics drugs and diagnostics.
As a result of the widespread economic hardship brought on by the pandemic, consumer demand has dropped as people try to cut back on discretionary spending. Over the projected period, these factors are likely to weigh on the growth rate of the global market for Epigenetics Drugs and Diagnostic Technologies. The global market for epigenetics drugs and diagnostics is likely to rebound as governments around the world begin to relax their enforced lockdowns.
Market Scope and Market Size –
Products, applications, technologies, and final consumers all play a role in dividing the epigenetics industry into several submarkets. Users will benefit from the market overview and market insights provided by these segments’ growth, which will enable them to make strategic decisions on the identification of core market applications.
Enzymes, instruments and consumables, kits, and reagents are all subsets of the epigenetics industry that can be broken down further by kind of product. Enzymes can be further subdivided into those that modify DNA, those that modify protein, and those that modify RNA. You can also categorise instruments and supplies by kind, such as next-generation sequencers, qPCR machines, mass spectrometers, sonicators, and so on. Bisulfite conversion kits, chromosomal inversion repair sequencing kits, ribosomal RNA sequencing kits, whole genome amplification kits, methylation analysis kits, and other types of kits are all subsets of the kits category. Antibodies, buffers, histones, magnetic beads, primers, and others make up the reagents subcategory.
Recent Developments –
By 2022, PacBio’s Sequel product line in the United States has integrated DNA methylation capabilities. It is hoped that by including this capability onto Sequel equipment, users will have more access to epigenomes using the company’s HiFi sequencing technology.
Proteintech Group, a company that creates nanobodies, antibodies, and recombinant proteins, will continue working with Active Motif through 2021.
Read more articles – Great Methods And Practices For Article Marketing Campaigns
NEBNext Enzymatic Methyl-seq (EM-seq) was released in the United States in 2019 by New England BioLabs as an alternative to bisulfite sequencing. In order to analyse methylation, this product makes use of enzymes.
Customization Available –
When it comes to cutting-edge exploratory studies, Zion Market Research is unrivalled. We are happy to provide our current and future clients with data and analysis that is tailored to their specific needs. You can modify the study to include data from clinical trials, a literature review, an examination of the remodeled market, and an examination of the product base, as well as a price trend analysis of your preferred brands in those nations.
Technology-based analysis as well as market portfolio techniques can be applied to a thorough examination of the competition. If you’d want us to provide information about any number of rival businesses, we can do so in the structure and style of information that you specify. The analysts on our team can also give you with raw excel files, pivot tables (Factbook), or help you make presentations using the information in the report.
Competitive Landscape –
When it comes to expanding their businesses and strengthening their R&D efforts in order to hasten the introduction of novel epigenetic technologies, providers of these services are putting an emphasis on mergers, collaborations, acquisitions, and partnerships.
In August 2021, Illumina Inc., a major American biotechnology firm, purchased Grail, a company specialising in the early identification of different cancers. Grail was enrolling patients for the trial to increase its dataset focused on the genome associated with cancer-causing epigenetic alterations in preparation for submitting an application to the FDA for approval of its Galleri test.
Key Players –
Illumina, Inc. (US)
Merck KGaA (Germany)
Element Biosciences, Inc.
Hoffmann-La Roche Ltd (Switzerland)
Eisai Co., Ltd. (Japan)
Novartis AG (Switzerland)
Abcam plc (UK)
Zymo Research Corporation. (US)
Agilent Technologies, Inc. (US)
EpiGentek Group Inc. (US)
BioVision Inc. (US)
By Type –
Reagents & Kits
By Applications –
By Regions –
Middle East and Africa